Who is a candidate for low-dose interleukin-2 therapy for kidney cancer?

Interleukin-2 (IL-2) has been administered to kidney cancer patients in lower doses, with encouraging results observed. This outpatient treatment plan provides another option for patients with metastatic kidney cancer.

Kidney cancer patients suitable for low-dose IL-2 therapy:

  • Must be diagnosed with metastatic kidney cancer (cancer that has spread to other parts of the body)
  • Must be out of bed more than 50 percent of the day
  • Have relatively normal function of heart, lungs, kidneys, and liver
  • Have brain metastases treated and stable
  • Should not take/use steroids or steroid-containing compounds

Continue Learning about Anti-HIV Agent

Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.